

Supporting Information

Polyfluoroalkylated Antipyridines In Pd-Catalyzed Transformations

**Evgeny V. Shchegolkov^a, Yanina V. Burgart^a, Daria A. Matsneva^a, Sophia S. Borisevich^b,
Renata A. Kadyrova^c, Iana R. Orshanskaya^c, Vladimir V. Zarubaev^c, Victor I. Saloutin^{a*}**

^a *Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskoi St., 22, Ekaterinburg 620990, Russia.*

^b *Ufa Institute of Chemistry, Russian Academy of Sciences, 71 October Ave., Ufa, 450054 Russia*

^c *Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, 14 Mira St., Saint-Petersburg, 197101, Russia*

*e-mail: saloutin@ios.uran.ru

Table of contents


Table S1. Direct C—H arylation of CF ₃ -antipyridine 1a (the best conditions for each type of aryl halogenide 2a-i are highlighted in color: yellow – compound is not isolated; green – compound is yielded in the pure form).....	5
Table S2. Optimization of the conditions for synthesis of 4-phenyl-5-trifluoromethyl-antipyridine 3a from bromo-antipyridine 4a	10
Table S3. Optimization of the conditions for synthesis of 4-phenyl-5-trifluoromethyl-antipyridine 3a from iodo-antipyridine 5a	11
Table S4. Optimization of the conditions for synthesis of 4-(phenylethynyl)-5-(trifluoromethyl)-antipyridine 6a from bromo-antipyridine 4a	12
Table S5. Optimization of the conditions for synthesis of 4-(phenylethynyl)-5-(trifluoromethyl)-antipyridine 6a from iodo-antipyridine 5a	13
Experimental.....	14
Synthesis of 5-(polyfluoroalkyl)-antipyridines 1a-d	14
Synthesis of 4-halogen-5-polyfluoroalkyl-antipyridines 4a-d, 5a,b	14
Synthesis of 4-aryl-5-(polyfluoroalkyl)-antipyridines 3a,c-l	16








Synthesis of 1-methyl-2-phenyl-4-(phenylethynyl)-5-(polyfluoroalkyl)-1,2-dihydro-3H-pyrazolon-3-ones 6a,b	19
Biological testing.....	20
Evaluation of cytotoxic properties of compounds.....	21
Evaluation of antiviral activity of compounds.....	21
References.....	22
Copies of ¹ H, ¹³ C, and ¹⁹ F NMR spectra of compounds.....	23
¹ H NMR spectrum of compound 4a in DMSO- <i>d</i> ₆	23
¹³ C NMR spectrum of compound 4a in DMSO- <i>d</i> ₆	24
¹⁹ F NMR spectrum of compound 4a in DMSO- <i>d</i> ₆	25
¹ H NMR spectrum of compound 4b in CDCl ₃	26
¹³ C NMR spectrum of compound 4b in CDCl ₃	27
¹⁹ F NMR spectrum of compound 4b in CDCl ₃	28
¹ H NMR spectrum of compound 4c in CDCl ₃	29
¹³ C NMR spectrum of compound 4c in CDCl ₃	30
¹⁹ F NMR spectrum of compound 4c in CDCl ₃	31
¹ H NMR spectrum of compound 4d in CDCl ₃	32
¹³ C NMR spectrum of compound 4d in CDCl ₃	33
¹⁹ F NMR spectrum of compound 4d in CDCl ₃	34
¹ H NMR spectrum of compound 5a in CDCl ₃	35
¹³ C NMR spectrum of compound 5a in CDCl ₃	36
¹⁹ F NMR spectrum of compound 5a in CDCl ₃	37
¹ H NMR spectrum of compound 5b in CDCl ₃	38
¹³ C NMR spectrum of compound 5b in CDCl ₃	39
¹⁹ F NMR spectrum of compound 5b in CDCl ₃	40
¹ H NMR spectrum of compound 3a in CDCl ₃	41
¹³ C NMR spectrum of compound 3a in CDCl ₃	42













¹⁹ F NMR spectrum of compound 3a in CDCl ₃	43
¹ H NMR spectrum of compound 3c in CDCl ₃	44
¹⁹ F NMR spectrum of compound 3c in CDCl ₃	45
¹ H NMR spectrum of compound 3d in CDCl ₃	46
¹³ C NMR spectrum of compound 3d in CDCl ₃	47
¹⁹ F NMR spectrum of compound 3d in CDCl ₃	48
¹ H NMR spectrum of compound 3e in CDCl ₃	49
¹³ C NMR spectrum of compound 3e in CDCl ₃	50
¹⁹ F NMR spectrum of compound 3e in CDCl ₃	51
¹ H NMR spectrum of compound 3f in CDCl ₃	52
¹³ C NMR spectrum of compound 3f in CDCl ₃	53
¹⁹ F NMR spectrum of compound 3f in CDCl ₃	54
¹ H NMR spectrum of compound 3g in DMSO- <i>d</i> ₆	55
¹³ C NMR spectrum of compound 3g in DMSO- <i>d</i> ₆	56
¹⁹ F NMR spectrum of compound 3g in DMSO- <i>d</i> ₆	57
¹ H NMR spectrum of compound 3h in CDCl ₃	58
¹³ C NMR spectrum of compound 3h in CDCl ₃	59
¹⁹ F NMR spectrum of compound 3h in CDCl ₃	60
¹ H NMR spectrum of compound 3i in CDCl ₃	61
¹³ C NMR spectrum of compound 3i in CDCl ₃	62
¹⁹ F NMR spectrum of compound 3i in CDCl ₃	63
¹ H NMR spectrum of compound 3j in CDCl ₃	64
¹³ C NMR spectrum of compound 3j in CDCl ₃	65
¹⁹ F NMR spectrum of compound 3j in CDCl ₃	66
¹ H NMR spectrum of compound 3k in CDCl ₃	67
¹³ C NMR spectrum of compound 3k in CDCl ₃	68













¹⁹ F NMR spectrum of compound 3k in CDCl ₃	69
¹ H NMR spectrum of compound 3l in CDCl ₃	70
¹³ C NMR spectrum of compound 3l in CDCl ₃	71
¹⁹ F NMR spectrum of compound 3l in CDCl ₃	72
¹ H NMR spectrum of compound 6a in CDCl ₃	73
¹³ C NMR spectrum of compound 6a in CDCl ₃	74
¹⁹ F NMR spectrum of compound 6a in CDCl ₃	75
¹ H NMR spectrum of compound 6b in CDCl ₃	76
¹³ C NMR spectrum of compound 6b in CDCl ₃	77
¹⁹ F NMR spectrum of compound 6b in CDCl ₃	78













Table S1. Direct C—H arylation of CF₃-antipyryne **1a** (the best conditions for each type of aryl halogenide **2a-i** are highlighted in color: yellow – compound is not isolated; green – compound is yielded in the pure form).



Entry	Conditions		Products 3a-g	Ratio of components (based on GLC mass spectrometry)			Preparative yield, %
	 2a-g	Catalyst, base, solvent, temperature, time		Compound 3	The initial antipyryne 1a	By-products	
1.	 2a	0.005 equiv. Pd(OAc) ₂ , 2 equiv. AcOK, CO(OEt) ₂ 150 °C, 24h	 3a	5	60	35	0
2.	 2a	0.02 equiv. Pd ₂ (dba) ₃ , 2 equiv. AcOK, CO(OEt) ₂ 150-160 °C, 24h	 3a	2	60	38	-
3.	 2a	0.02 equiv. Pd ₂ (dba) ₃ , 0.04 equiv. XPhos, 2.5 equiv. K ₂ CO ₃ , EtOH-H ₂ O	 3a	0	89	11	-

		100 °C, 24h					
4.	 2b	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3b	12	54	34	0
5.	 2c	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3c	13	56	31	0
6.	 2d	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3c	21	54	25	10
7.	 2d	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. AcOK, CO(OEt) ₂ 150-160 °C, 24h	 3c	10	55	35	-
8.	 2e	0.02 equiv. Pd(OAc) ₂ , 1 equiv. AcOK, CO(OEt) ₂ 150-160 °C, 24h	 3d	16	74	9	-
9.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. AcOK, CO(OEt) ₂ 150-160 °C, 24h	 3d	20	56	23	12

10.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.5 equiv. AcOK, CO(OEt) ₂ 150-160 °C, 24h	 3d	6	82	12	-
11.	 2e	0.02 equiv. Pd(OAc) ₂ , 2 equiv. AcOK, CO(OEt) ₂ 150-160 °C, 24h	 3d	9	47	43	-
12.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. AcOK, DMA 150-160 °C, 24h	 3d	resinification			-
13.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. AcOK, toluene 150-160 °C, 24h	 3d	1	79	20	-
14.	 2e	0.02equiv. Pd(OAc) ₂ , 1.3 equiv. AcOK, 1,4-dioxane 150-160 °C, 24h	 3d	5	73	22	-
15.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₂ CO ₃ , CO(OEt) ₂ 150-160 °C, 24h	 3d	4	80	15	-

16.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. AcOK, toluene 150-160 °C, 24h	 3d	1	79	20	-
17.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. AcOK, 1,4-dioxane 150-160 °C, 24h	 3d	5	73	22	-
18.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₂ CO ₃ , CO(OEt) ₂ 150-160 °C, 24h	 3d	4	80	15	-
19.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. Cs ₂ CO ₃ , CO(OEt) ₂ 150-160 °C, 24h	 3d	0	81	15	-
20.	 2e	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3d	6	76	18	-
21.	 2e	0.02 equiv. Pd ₂ (dba) ₃ , 0.04 equiv. XPhos, 2.5 equiv. K ₂ CO ₃ , EtOH-H ₂ O 100 °C, 8h	 3d	0	53	27	-














22.	 2e	0.02 equiv. Pd ₂ (dba) ₃ , 0.04 equiv. XPhos, 2 equiv. AcOK, CO(OEt) ₂ 150-160 °C, 24h	 3d	5	45	50	-
23.	 2e	0.02 equiv. Pd ₂ (dba) ₃ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3d	8	78	12	-
24.	 2f	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3d	42	38	20	27
25.	 2g	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3e	7	54	39	0
26.	 2h	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3e	40	47	13	25
27.	 2i	0.02 equiv. Pd(OAc) ₂ , 1.3 equiv. K ₃ PO ₄ , CO(OEt) ₂ 150-160 °C, 24h	 3f	32	52	16	23

Table S2. Optimization of the conditions for synthesis of 4-phenyl-5-trifluoromethyl-antipyrene **3a** from bromo-antipyrene **4a**




Entry	Conditions		Ratio of components (based on GLC mass spectrometry)			
	[Pd]	Ligand	Product 3a	Initial Br-antipyrene 4a	Debromination product – antipyrene 1a	Impurities
1 ^a	0.05 equiv. $\text{Pd(PPh}_3)_4$		2	85	3	10
2	0.05 equiv. $\text{Pd(PPh}_3)_4$		72	-	10	18
3	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. $\text{P}(o\text{-Tol})_3$	76	2	11	11
4	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. $\text{P}(p\text{-Tol})_3$	62	3	14	21
5	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. XPhos	86	-	6	8
6	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. Xantphos	81	-	4	15
7	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. BINAP	76	-	8	16
8 ^b	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. XPhos	62	-	5	33

^a Solvent - THF-H₂O (3:4)

^b Reaction was performed in a closed vial in microwave synthesizer “CEM Discover”, MW 100 Wt, 100°C, 8 h

Table S3. Optimization of the conditions for synthesis of 4-phenyl-5-trifluoromethyl-antipyrene **3a** from iodo-antipyrene **5a**




Entry	Conditions			Ratio of components (based on GLC mass spectrometry)			
	[Pd]	Ligand	T, °C	Product 3a	Initial I-antipyrene 5a	Deiodation product – antipyrene 1a	Impurities
1	0.05 equiv. Pd(PPh ₃) ₄		100	25	-	47	28
2	0.02 equiv. Pd ₂ (dba) ₃	0.04 equiv. Xantphos	100	33	-	59	8
3	0.02 equiv. Pd ₂ (dba) ₃	0.04 equiv. BINAP	100	27	-	57	16
4	0.02 equiv. Pd ₂ (dba) ₃	0.04 equiv. XPhos	100	32	-	55	13
5 ^a	0.02 equiv. Pd ₂ (dba) ₃	0.04 equiv. XPhos	100	32	-	60	8
6^b	0.02 equiv. Pd₂(dba)₃	0.04 equiv. XPhos	rt	100	-	-	-
7 ^b	0.05 equiv. Pd(PPh ₃) ₄		rt	31	-	42	27

^a Base Cs₂CO₃ (2.5 equiv.)


^b Time of reaction is 72 h

Table S4. Optimization of the conditions for synthesis of 4-(phenylethynyl)-5-(trifluoromethyl)-antipyrene **6a** from bromo-antipyrene **4a**



Entry	Conditions				Ratio of components (based on GLC mass spectrometry)			
	[Pd]	Ligand	T, °C	Time, h	Product 6a	Initial Br-antipyrene 4a	Debromination product 1a	1,4-diphenyl-1,3-butadiyne + impurities
1	0.05 equiv. $\text{Pd}(\text{PPh}_3)_4$		80	12	29	36	-	35
2	0.05 equiv. $\text{Pd}(\text{PPh}_3)_4$		100	6	35	12	-	53
3	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. BINAP	80	12	8	49	-	43
4	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. Xantphos	80	12	30	34	-	36
5	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. XPhos	80	12	18	37	1	44
6	0.02 equiv. $\text{Pd}_2(\text{dba})_3$	0.04 equiv. XPhos	100	6	36	17	1	46

Table S5. Optimization of the conditions for synthesis of 4-(phenylethynyl)-5-(trifluoromethyl)-antipyridine **6a** from iodo-antipyridine **5a**



Entry	Conditions			Ratio of components (based on GLC mass spectrometry)			
	Solvent	T, °C	Time, h	Product 6a	Initial I-antipyridine 5a	Deiodation product 1a	1,4-diphenyl-1,3-butadiyne + impurities
1	Toluene	100	14	2	-	8	90
2	1,4-Dioxane	100	14	13	-	48	39
3	Acetonitrile	100	14	25	-	45	30
4	Acetonitrile	50	4	35	-	43	23
5	Acetonitrile	rt	4	25	70	-	5
6	Acetonitrile	rt	72	75	-	-	25

Experimental

All solvents, chemicals, and reagents were obtained commercially and used without purification. Melting points were measured in open capillaries on a Stuart SMP30 melting point apparatus and were uncorrected. The IR spectra were recorded on Perkin Elmer «Spectrum Two» using frustrated total internal reflection accessory with diamond crystal at ν 4000–400 cm^{-1} . The ^1H and ^{19}F NMR spectra were registered on a Bruker DRX-400 (400 or 376 MHz, respectively) or a Bruker Avance^{III} 500 (500 or 470 MHz, respectively). The ^{13}C NMR spectra were recorded on a Bruker Avance^{III} 500 (125 MHz). The internal standard is SiMe_4 (for ^1H and ^{13}C NMR spectra) and C_6F_6 (for ^{19}F NMR spectra, δ –162.9 ppm). The microanalyses (C, H, N) were carried out on a PerkinElmer PE 2400 series II elemental analyzer. The column chromatography was performed on Silica gel 60 (0.062–0.2 mm).

Crystallographic data

The X-ray studies were performed on “Xcalibur 3 CCD” diffractometer with graphite monochromator, ω scanning with 1° step, $\lambda(\text{MoK}\alpha)$ 0.71073 Å radiation, T 295(2) K. Empirical absorption correction was applied. Using Olex2 [1], the structure was solved with the ShelXS structure solution program using Direct Methods and refined with the ShelXL [2] refinement package using Least Squares minimization. All non-hydrogen atoms were refined in the anisotropic approximation; H-atoms of the OH-groups were localized from the electron density peaks and refined independently; H-atoms at the C-H bonds were refined in the “rider” model with dependent displacement parameters. Empirical absorption correction was carried out through spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm by a program “CrysAlisPro 1.171.39.38a” (Rigaku Oxford Diffraction, 2017).

Synthesis of 5-(polyfluoroalkyl)-antipyrines **1a-d**

The initial antipyrines **1a-d** were synthesized by the known method [3].

Synthesis of 4-halogen-5-polyfluoroalkyl-antipyrines **4a-d**, **5a,b**.

A mixture of antipyrine **1a-d** (1 mmol) and N-halogensuccinimide (1.2 mmol) in CHCl_3 (20 ml) was stirring at the room temperature for 3–4 h. Then, it was added water (20 ml), the organic lay was separated, dried over Na_2SO_4 and distilled off on a rotary evaporator. The residue was re-crystallized from *n*-hexane.

4-Bromo-1-methyl-2-phenyl-5-(trifluoromethyl)-1,2-dihydro-3H-pyrazol-3-one (4a). Yield 85%, light-yellow powder, mp 79–80 °C. ^1H NMR ($\text{DMSO-}d_6$, 400 MHz): δ 3.22 (s, 3H, Me); 7.46–7.49, 7.46–7.61 (all m, 5H, Ph). ^{13}C NMR ($\text{DMSO-}d_6$, 125 MHz): δ 37.74 (Me); 92.80 (q, J 2.8 Hz, C—Br); 118.96 (q, J 272.8 Hz, CF_3); 125.76, 128.66, 129.49, 132.39 (Ph); 140.23 (q, J 37.0 Hz, $\underline{\text{C}}$ — CF_3); 159.11 (C=O). ^{19}F NMR ($\text{DMSO-}d_6$, 376 MHz): δ 102.85 (s, CF_3). IR: ν

1690 (C=O); 1489, 1457, 1400 (C=C); 1061-1172 (CF), 704-759 (CBr) cm^{-1} . Anal. calcd for $\text{C}_{11}\text{H}_8\text{BrF}_3\text{N}_2\text{O}$: C, 41.15; H, 2.51; N, 8.72. Found: C, 41.23; H, 2.67; N, 8.79.

4-Bromo-1-methyl-5-(pentafluoroethyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (4b).

Yield 83%, white powder, mp 95 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 3.20 (s, 3H, Me); 7.41-7.43, 7.51-7.53 (both m, 5H, Ph). ^{13}C NMR (CDCl_3 , 125 MHz): δ 38.60-38.66 (m, Me); 98.74 (t, J 1.9 Hz, C—Br); 109.98 (tq, J 258.5, 41.3 Hz, CF_2); 118.37 (qt, J 287.5, 37.0 Hz, CF_3); 125.11, 128.59, 129.64, 132.84 (Ph); 140.67 (t, J 27.1 Hz, $\underline{\text{C}}$ — CF_2); 160.09 (C=O). ^{19}F NMR (CDCl_3 , 376 MHz): δ 49.22-49.23 (m, 2F, CF_2), 78.60 (t, J 3.3 Hz, 3F, CF_3). IR: ν 1687 (C=O); 1487, 1458, 1330 (C=C); 1113-1210 (CF) cm^{-1} . Anal. calcd for $\text{C}_{12}\text{H}_8\text{BrF}_5\text{N}_2\text{O}$: C, 38.84; H, 2.17; N, 7.55. Found: C, 38.96; H, 2.17; N, 7.71.

4-Bromo-5-(heptafluoropropyl)-1-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one

(4c). Yield 79%, white powder, mp 97-98 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 3.20 (s, 3H, Me); 7.41-7.42, 7.51-7.53 (both m, 5H, Ph). ^{13}C NMR (CDCl_3 , 125 MHz): δ 38.64-38.71 (m, Me); 99.03 (unsolv. t, C—Br); 108.76 (tq, J 266.8, 33.6 Hz, β - CF_2); 112.07 (tt, J 259.7, 38.5 Hz, α - CF_2); 117.49 (qt, J 288.0, 33.6 Hz, CF_3); 125.19, 128.65, 129.62, 132.85 (Ph); 140.65 (t, J 27.5 Hz, $\underline{\text{C}}$ — CF_2); δ 160.13 (C=O). ^{19}F NMR (CDCl_3 , 376 MHz): δ 36.34-36.40 (m, 2F, CF_2); 52.15-52.21 (m, 2F, CF_2); 81.68 (t, J 9.7 Hz, 3F, CF_3). IR: ν 1695 (C=O), 1497, 1459, 1388, 1337 (C=C), 1236-1109 (CF) cm^{-1} . Anal. calcd for $\text{C}_{13}\text{H}_8\text{BrF}_7\text{N}_2\text{O}$: C, 37.08; H, 1.19; N, 6.75. Found: C, 37.09; H, 2.14; N, 6.75.

4-Bromo-1-methyl-5-(nonafluorobutyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (4d).

Yield 75%, white powder, mp 99-100 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 3.20 (s, 3H, Me); 7.40-7.44, 7.51-7.55 (both m, 5H, Ph). ^{13}C NMR (CDCl_3 , 125 MHz): δ 38.67-38.68 (m, Me); 99.14 (unsolv. t, C—Br); 108.50-114.76 (m, 3 CF_2); 117.25 (qt, J 288.6, 33.0 Hz, CF_3); 125.19, 128.65, 129.66, 132.85 (Ph); 140.66 (t, J 27.6 Hz, $\underline{\text{C}}$ — CF_2); δ 160.13 (C=O). ^{19}F NMR (CDCl_3 , 376 MHz): δ 35.83-35.92, 39.97-40.00, 52.87-52.94 (all m, 6F, 3 CF_2); 80.94-81.00 (m, 3F, CF_3). IR: ν 1677 (C=O), 1497, 1462, 1396 (C=C), 1114-1217 (CF) cm^{-1} . Anal. calcd for $\text{C}_{14}\text{H}_8\text{BrF}_9\text{N}_2\text{O}$: C, 35.69; H, 1.71; N, 3.40. Found: C, 35.78; H, 1.91; N, 6.09.

4-Iodo-1-methyl-2-phenyl-5-(trifluoromethyl)-1,2-dihydro-3H-pyrazol-3-one (5a).

Yield 80%, yellow powder, mp 85 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 3.24 (s, 3H, Me); 7.40-7.43, 7.49-7.53 (both m, 5H, Ph). ^{13}C NMR (CDCl_3 , 125 MHz): δ 38.26 (q, J 2.0 Hz, Me); 64.90 (q, J 2.1 Hz, C—I); 118.86 (q, J 273.3 Hz, CF_3); 124.78, 128.31, 129.56, 132.99 (Ph); 145.97 (q, J 37.1 Hz, $\underline{\text{C}}$ — CF_3); 162.12 (C=O). ^{19}F NMR (CDCl_3 , 376 MHz): δ 101.31 (s, CF_3). IR: ν 1661 (C=O), 1594, 1552, 1496 (C=C), 1024-1245 (CF) cm^{-1} . Anal. calcd for $\text{C}_{11}\text{H}_8\text{F}_3\text{IN}_2\text{O}$: C, 35.89; H, 2.19; N, 7.61. Found: C, 36.10; H, 2.23; N, 7.69.

4-Iodo-1-methyl-5-(pentafluoroethyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (5b).

Yielded 75 %, yellow powder, mp 80 °C. ¹H NMR (CDCl₃, 400 MHz): δ 3.23 (s, 3H, Me); 7.40-7.42, 7.50-7.54 (both m, 5H, Ph). ¹³C NMR (CDCl₃, 125 MHz): δ 38.72 (br.s, Me); 68.08 (unsolv. t, C-I); 109.75 (tq, *J* 258.7, 41.1 Hz, CF₂); 118.31 (qt, *J* 287.7, 37.0 Hz, CF₂); 125.17, 128.54, 129.60 (Ph); 143.92 (t, *J* 27.0 Hz, C—CF₂); 162.20 (C=O). ¹⁹F NMR (CDCl₃, 376 MHz): δ 50.33 (q, *J* 3.5 Hz, CF₂), 78.96 (t, *J* 3.5 Hz, CF₃). IR: ν 1667 (C=O), 1496, 1485, 1457 (C=C), 1019-1213 (CF) cm⁻¹. Anal. calcd for C₁₂H₈F₅IN₂O: C, 34.73; H, 1.93; N, 6.70. Found: C, 34.69; H, 1.91; N, 6.86.

Synthesis of 4-aryl-5-(polyfluoroalkyl)-antipyrines 3a,c-l

Method A. A screw-neck vial was flushed with argon and charged with 4-bromo-5-(polyfluoroalkyl)-antipyrine **4a-d** (1 mmol), arylboronic acid (1.2 mmol) (phenylboronic acid - 122 mg, (4-(methylthio)phenyl)boronic acid - 168 mg), XPhos (0.04 mmol, 19 mg), Pd₂(dba)₃ (0.02 mmol, 18 mg), K₂CO₃ (2.5 mmol, 345 mg), EtOH (4 ml), and water (1 ml). The vial was repeatedly flushed with argon, closed tightly and heated at 100 °C for 8 h. After cooling, another portion of ethanol (20 ml) was added and a mixture was filtered through a small quantity of silica gel. The solvent was evaporated in vacuo, and the residue was purified by column chromatography on silica gel using a mixture of CHCl₃ and EtOAc (4:1).

Method B. Similarly to method A from 1 mmol of 4-iodo-5-(polyfluoroalkyl)-antipyrine **5a,b** at the room temperature for 72 h.

Method C. A screw-neck vial was flushed with argon and charged with 5-(trifluoromethyl)-antipyrine **1a** (1 mmol, 242 mg), arylhalogenide (1.5 mmol), Pd(OAc)₂ (0.02 mmol, 4.5 mg), K₃PO₄ (1.3 mmol, 275 mg), and diethyl carbonate (4 ml). The vial was repeatedly flushed with argon, closed tightly and heated at 150-160 °C for 20 h. After cooling, the solvent was evaporated in vacuo, and the residue was purified by column chromatography on silica gel using a mixture of *n*-hexane and EtOAc (4:1).

2,4-Diphenyl-1-methyl-5-(trifluoromethyl)-1,2-dihydro-3H-pyrazol-3-one (3a). Yield 69% (*method A*), 89% (*method B*), white powder, mp 94-95 °C. ¹H NMR (CDCl₃, 500 MHz): δ 3.25 (s, 3H, Me); 7.34-7.43, 7.47-7.49, 7.50-7.52 (all m, 10H, 2 Ph). ¹³C NMR (CDCl₃, 125 MHz): δ 38.13 (Me); 117.93 (=C—Ph); 119.91 (q, *J* 272.9 Hz, CF₃); 124.46, 127.67, 128.09, 128.15, 128.59, 129.42, 129.77, 133.40 (2 Ph); 140.86 (q, *J* 36.8 Hz, C—CF₃); 162.44 (C=O). ¹⁹F NMR (CDCl₃, 470 MHz): δ 102.96 (s, CF₃). IR: 1678 (C=O), 1413, 1450, 1495, 1596 (C=C), 1076-1153 (CF) cm⁻¹. Anal. calcd for C₁₇H₁₃F₃N₂O: C, 64.15; H, 4.12; N, 8.80. Found: C, 63.67; H, 4.00; N, 8.56.

1-Methyl-2-phenyl-5-(trifluoromethyl)-4-[4-(cyano)phenyl]-1,2-dihydro-3H-pyrazol-3-one (3c):antipyrene (1a) – 83:17. Yield 10% (*method C*). ¹H NMR (CDCl₃, 500 MHz): δ 3.32 (s, 3H, Me); 7.40-7.56 (m, 5H, Ph); 7.61, 7.70 (both d, *J* 8.3 Hz, 4H, C₆H₄). ¹⁹F NMR (CDCl₃, 470 MHz): δ 103.05 (s, CF₃).

1-Methyl-2-phenyl-5-(trifluoromethyl)-4-[4-(nitro)phenyl]-1,2-dihydro-3H-pyrazol-3-one (3d). Yield 27% (*method C*), off-white powder, mp 103-104 °C. ¹H NMR (CDCl₃, 500 MHz): δ 3.35 (s, 3H, Me); 7.42-7.49, 7.54-7.57 (both m, 5H, Ph); 7.68, 8.28 (both d, *J* 8.6 Hz, 4H, C₆H₄). ¹³C NMR (CDCl₃, 125 MHz): δ 37.67 (q, *J* 2.0 Hz, Me); 114.22 (=C—Ar); 119.62 (q, *J* 273.0 Hz, CF₃); 123.36, 125.14, 128.48, 129.67, 130.83, 132.81, 135.14, 147.65 (C₆H₄ and Ph); 140.46 (q, *J* 37.2 Hz, C⁴—CF₃); 161.58 (C=O). ¹⁹F NMR (CDCl₃, 470 MHz): δ 103.07 (s, CF₃). IR: 1660 (C=O), 1627, 1595, 1493, 1455, 1441, 1420 (C=C), 1155-1095 (CF) cm⁻¹. Anal. calcd for C₁₇H₁₂F₃N₃O₃: C, 56.20; H, 3.33; N, 11.57. Found: C, 56.32; H, 3.27; N, 11.39.

1-Methyl-2-phenyl-5-(trifluoromethyl)-4-[4-(trifluoromethyl)phenyl]-1,2-dihydro-3H-pyrazol-3-one (3e). Yield 25% (*method C*), off-white powder, mp 99-100 °C. ¹H NMR (CDCl₃, 500 MHz): δ 3.30 (s, 3H, Me); 7.39-7.42, 7.48-7.50, 7.52-7.55 (all m, 5H, Ph); 7.61, 7.68 (both d, *J* 8.1 Hz, 4H, C₆H₄). ¹³C NMR (CDCl₃, 125 MHz): δ 37.81 (q, *J* 1.9 Hz, Me); 115.62 (=C—Ar); 119.70 (q, *J* 273.0 Hz, CF₃); 121.86 (q, *J* 270.0 Hz, C₆H₄—CF₃); 124.85, 128.15, 129.56, 133.01 (Ph); 125.13 (q, *J* 3.7 Hz, C^o Ar^F); 130.22 (q, *J* 1.2 Hz, C^m Ar^F); 130.77 (q, *J* 32.6 Hz, Cⁱ Ar^F); 131.98 (q, *J* 1.1 Hz, C^p Ar^F); 140.72 (q, *J* 37.2 Hz, C⁴—CF₃); 161.95 (C=O). ¹⁹F NMR (CDCl₃, 470 MHz): δ 98.99, 103.01 (both s, 6F, 2CF₃). IR: 1666 (C=O), 1620, 1593, 1496, 1457, 1442, 1421 (C=C), 1165-1068 (CF) cm⁻¹. Anal. calcd for C₁₈H₁₂F₆N₂O: C, 55.97; H, 3.13; N, 7.25. Found: C, 55.69; H, 3.05; N, 7.36.

Colorless single crystals of compound **3e** were obtained by crystallization from a mixture of CHCl₃:*n*-hexane:EtOAc – 4:4:1. Main crystallographic data for **3e**: C₁₈H₁₂F₆N₂O, *M* 386.30, space group P $\bar{1}$, triclinic, *a* 8.6416(7), *b* 11.0188(9), *c* 18.0722(14) Å, α 93.734(6), β 90.935(6), γ 95.221(6)°, *V* 1709.6(2) Å³, *Z* 4, *D*_{calc} 1.501 g·cm⁻³, μ 0.139 mm⁻¹, 584 refinement parameters, 8397 reflections measured, 3326 unique reflections which were used in all calculations. The final *R* is 0.057. CCDC 2110385 contains the supplementary crystallographic data for this compound.

1-Methyl-2-phenyl-5-(trifluoromethyl)-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-3H-pyrazol-3-one (3f). Yield 23% (*method C*), white powder, mp 105-106 °C. ¹H NMR (CDCl₃, 500 MHz): δ 3.30 (s, 3H, Me); 7.39-7.42, 7.49-7.54, 7.63-7.68, 7.77 (all m, 9H, C₆H₄ and Ph). ¹³C NMR (CDCl₃, 125 MHz): δ 37.90 (q, *J* 1.9 Hz, Me); 115.76 (=C—Ar); 119.74 (q, *J* 273.0 Hz, CF₃); 121.84 (q, *J* 255.8 Hz, C₆H₄—CF₃); 124.80, 128.12, 129.57, 133.11 (Ph); 125.33 (q, *J* 3.7 Hz, C Ar^F); 130.75 (q, *J* 32.6 Hz, C^{3'} Ar^F); 126.81, 128.69, 129.07, 133.17 (4C Ar^F); 140.85 (q, *J* 37.1 Hz, C⁴—CF₃); 162.05 (C=O). ¹⁹F NMR (CDCl₃, 470 MHz): δ 99.00, 102.91 (both s, 6F,

2CF₃). IR: 1675 (C=O), 1624, 1596, 1496, 1459, 1411 (C=C), 1154-1074 (CF) cm⁻¹. Anal. calcd for C₁₈H₁₂F₆N₂O: C, 55.97; H, 3.13; N, 7.25. Found: C, 55.72; H, 3.15; N, 7.29.

1-Methyl-4-(4-(methylthio)phenyl)-5-(trifluoromethyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (3g). Yield 59% (*method A*), 79% (*method B*), beige powder, mp 113-115 °C. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 2.51 (s, 3H, SMe); 3.23 (s, 3H, Me); 7.34-7.35, 7.50-7.51, 7.57-7.59 (all m, 10H, 2 Ph). ¹³C NMR (DMSO-*d*₆, 125 MHz): δ 14.31 (SMe); 39.16 (Me); 115.28 (unsolv. q, =C—Ar); 119.76 (q, *J* 272.7 Hz, CF₃); 124.57, 125.17, 125.21, 127.97, 129.41, 130.06, 132.95, 138.91 (2 Ph); 138.92 (q, 36.2 Hz, C—CF₃); 161.29 (C=O). ¹⁹F NMR (DMSO-*d*₆, 470 MHz): δ 104.68 (s, CF₃). IR: 1680 (C=O), 1412, 1429, 1456, 1494 (C=C), 1094-1157 (CF) cm⁻¹. Anal. calcd for C₁₈H₁₅F₃N₂OS. C, 59.33; H, 4.15; N, 7.69. Found: C, 56.47; H, 3.66; N, 6.27.

2,4-Diphenyl-1-methyl-5-(pentafluoroethyl)-1,2-dihydro-3H-pyrazol-3-one (3h). Yield 68% (*method A*), 86% (*method B*), beige powder, mp 155 °C. ¹H NMR (CDCl₃, 500 MHz): δ 3.23 (s, 3H, Me); 7.31-7.45, 7.48-7.57 (all m, 10H, 2 Ph). ¹³C NMR (CDCl₃, 125 MHz): δ 38.70 (Me); 110.60 (tq, *J* 257.4, 40.7 Hz, CF₂); 118.45 (qt, *J* 287.3, 37.0 Hz, CF₂); 121.49 (=C—Ph); 124.66, 127.77, 127.97, 128.33, 128.45, 129.42, 129.65, 130.07 (2 Ph); 133.50 (t, *J* 27.4 Hz, C—CF₂); 162.63 (C=O). ¹⁹F NMR (CDCl₃, 470 MHz): δ 52.38 (br.s, 2F, CF₂), 78.37 (t, *J* 3.2 Hz, 3F, CF₃). IR: 1670 (C=O), 1122, 1139, 1184, 1216, 1223 (C=C), 1018-1079 (CF) cm⁻¹. Anal. calcd for C₁₈H₁₃F₅N₂O: C, 58.70; H, 3.56; N, 7.61. Found: C, 57.88; H, 3.34; N, 7.44.

1-Methyl-4-(4-(methylthio)phenyl)-5-(pentafluoroethyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (3i). Yield 54% (*method A*), 73% (*method B*), beige powder, mp 99-100 °C. ¹H NMR (CDCl₃, 500 MHz): δ 2.50 (s, 3H, SMe); 3.22 (s, 3H, Me); 7.26-7.31, 7.38-7.40, 7.48-7.54 (all m, 10H, 2 Ph). ¹³C NMR (CDCl₃, 125 MHz): δ 15.47 (SMe); 38.69 (Me); 110.60 (tq, *J* 257.3, 40.6 Hz, CF₂); 118.45 (qt, *J* 287.3, 37.1 Hz, CF₂); 120.85 (=C—Ar); 124.71, 124.83, 125.82, 127.85, 129.44, 130.42, 133.41, 139.24 (2 Ph); 138.97 (t, *J* 27.5 Hz, C—CF₂); 162.59 (C=O). ¹⁹F NMR (CDCl₃, 470 MHz): δ 52.42 (br.s, 2F, CF₂), 78.40 (t, *J* 3.3 Hz, 3F, CF₃). IR: 1671 (C=O), 1460, 1459, 1587 (C=C), 1147-1219 (CF) cm⁻¹. Anal. calcd for C₁₉H₁₅F₅N₂OS: C, 55.07; H, 3.65; N, 6.76. Found: C, 55.27; H, 3.60; N, 6.47.

2,4-Diphenyl-5-(heptafluoropropyl)-1-methyl-1,2-dihydro-3H-pyrazol-3-one (3j). Yield 65% (*method A*), beige powder, mp 160 °C. ¹H NMR (CDCl₃, 500 MHz): δ 3.23 (s, 3H, Me); 7.37-7.38, 7.48-7.54 (all m, 10H, 2 Ph). ¹³C NMR (CDCl₃, 125 MHz): δ 38.84 (Me); 108.68 (tq, *J* 266.7, 38.0 Hz, β-CF₂); 112.62 (tt, *J* 258.0, 32.9 Hz, α-CF₂); 117.56 (qt, *J* 288.0, 33.7 Hz, CF₃); 121.84 (=C—Ph); 124.68, 127.81, 127.96, 128.34, 128.47, 129.45, 130.09 (2 Ph); 139.39 (t, *J* 27.7 Hz, C—CF₂); 162.67 (C=O). ¹⁹F NMR (CDCl₃, 470 MHz): δ 36.34-36.41 (m, 2F, CF₂); 55.19 (q, *J* 9.7 Hz, 2F, CF₂); 81.66 (t, *J* 9.7 Hz, 3F, CF₃). IR: 1671 (C=O), 1338, 1498, 1593

(C=C), 1116-1235 (CF) cm^{-1} . Anal. calcd for $\text{C}_{19}\text{H}_{13}\text{F}_7\text{N}_2\text{O}$: C, 54.55; H, 3.13; N, 6.70. Found: C, 52.76; H, 3.16; N, 6.48.

5-(Heptafluoropropyl)-1-methyl-4-(4-(methylthio)phenyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (3k). Yield 52% (*method A*), beige powder, mp 155-156 °C. ^1H NMR (CDCl_3 , 500 MHz): δ 2.50 (s, 3H, SMe); 3.22 (s, 3H, Me); 7.26-7.28, 7.36-7.40, 7.47-7.52 (all m, 10H, 2 Ph). ^{13}C NMR (CDCl_3 , 125 MHz): δ 15.49 (SMe); 38.86-38.88 (m, Me); 107.73 (tq, J 266.8, 37.9 Hz, $\beta\text{-CF}_2$); 112.66 (tt, J 258.0, 32.9 Hz, $\alpha\text{-CF}_2$); 117.59 (qt, J 288.2, 33.8 Hz, CF_3); 121.25 ($=\underline{\text{C}}$ —Ph); 124.77, 124.89, 125.82, 127.91, 129.50, 130.48, 133.48, 139.29 (2 Ph); 139.01 (t, J 28.0 Hz, $\underline{\text{C}}$ — CF_2); 162.67 (C=O). ^{19}F NMR (CDCl_3 , 470 MHz): δ 36.36-36.46 (m, 2F, CF_2), 55.21-55.23 (m, 2F, CF_2), 81.70 (t, J 9.8 Hz, 3F, CF_3). IR: 1674 (C=O), 1405, 1459, 1587 (C=C), 1094-1240 (CF) cm^{-1} . Anal. calcd for $\text{C}_{20}\text{H}_{15}\text{F}_7\text{N}_2\text{OS}$: C, 51.73; H, 3.26; N, 6.03. Found: C, 51.92; H, 3.33; N, 6.01.

2,4-Diphenyl-1-methyl-5-(nonafluorobutyl)-1,2-dihydro-3H-pyrazol-3-one (3l). Yield 67% (*method A*), beige powder, mp 97-98 °C. ^1H NMR (CDCl_3 , 500 MHz): δ 3.23 (s, 3H, Me); 7.36-7.42, 7.48-7.54 (all m, 10H, 2 Ph). ^{13}C NMR (CDCl_3 , 125 MHz): δ 38.84-38.88 (m, Me); 106.39-115.55 (m, 3 CF_2); 117.25 (qt, J 288.3, 33.2 Hz, CF_3); 121.92 ($=\underline{\text{C}}$ —Ph); 124.69, 127.81, 127.96, 128.34, 128.36, 129.45, 130.09 (2 Ph); 139.25 (t, J 27.8 Hz, $\underline{\text{C}}$ — CF_2); 162.67 (C=O). ^{19}F NMR (CDCl_3 , 470 MHz): δ 35.84-35.93, 39.90-39.97, 55.86-55.93 (all m, 3 CF_2), 80.92 (t, J 9.8 Hz, 3F, CF_3). IR: 1669 (C=O), 1458, 1498, 1593, 1626 (C=C), 1130-1239 (CF) cm^{-1} . Anal. calcd for $\text{C}_{20}\text{H}_{13}\text{F}_9\text{N}_2\text{O}$: C, 51.29; H, 2.80; N, 5.98. Found: C, 51.29; H, 2.88; N, 5.91.

Synthesis of 1-methyl-2-phenyl-4-(phenylethynyl)-5-(polyfluoroalkyl)-1,2-dihydro-3H-pyrazolon-3-ones **6a,b**.

A screw-neck vial was flushed with argon and charged with 4-iodo-5-(polyfluoroalkyl)-antipyrine **5a,b** (1 mmol), phenylacetylene (1.5 mmol, 153 mg), XPhos (0.04 mmol, 19 mg), $\text{Pd}_2(\text{dba})_3$ (0.02 mmol, 18 mg), CuI (0.1 mmol, 19 mg), DIPEA (2 mmol, 258 mg), and MeCN (4 ml). The vial was repeatedly flushed with argon, closed tightly and a mixture was stirring at the room temperature for 72 h. After cooling, the solvent was evaporated in vacuo and the crosslinking product - 1,4-diphenyl-1,3-butadiyne was removed by flash-chromatography on silica gel (eluent – CHCl_3). Then, the product **6a** was purified by column chromatography on silica gel using a mixture of *n*-hexane and EtOAc (4:1) or the compound **6b** was re-crystallized from a mixture of *n*-hexane and EtOAc (4:1).

1-Methyl-2-phenyl-4-(phenylethynyl)-5-(trifluoromethyl)-1,2-dihydro-3H-pyrazolon-3-one (6a). Yield 60 %, brown crystals, mp 124-125 °C. ^1H NMR (CDCl_3 , 500 MHz): δ 3.27 (s, 3H, Me); 7.33-7.34, 7.41-7.43, 7.51-7.55 (all m, 10H, 2 Ph). ^{13}C NMR (CDCl_3 , 125

MHz): δ 37.27-37.28 (m, Me); 76.45, 97.75 ($-\text{C}\equiv\text{C}-$); 99.95 (unsolv. q, C^4); 119.22 (q, J 272.9 Hz, CF_3); 122.59, 125.40, 128.25, 128.54, 128.73, 129.63, 131.78, 131.74 (2 Ph); 142.83 (q, J 37.2 Hz, $\underline{\text{C}}-\text{CF}_3$); 161.85 ($\text{C}=\text{O}$). ^{19}F NMR (CDCl_3 , 470 MHz): δ 100.83 (s, CF_3). IR: 1678 ($\text{C}=\text{O}$); 1416, 1457, 1585 ($\text{C}=\text{C}$); 1118-1174 (CF) cm^{-1} . Anal. calcd for $\text{C}_{19}\text{H}_{13}\text{F}_3\text{N}_2\text{O}$: C, 66.67; H, 3.83; N, 6.76. Found: C, 66.66; H, 3.86; N, 7.91.

1-Methyl-5-(pentafluoroethyl)-2-phenyl-4-(phenylethynyl)-1,2-dihydro-3H-pyrazolon-3-one (6b). Yield 65 %, brown crystals, mp 129-130 °C. ^1H NMR (CDCl_3 , 500 MHz): δ 3.26 (s, 3H, Me); 7.33, 7.40-7.44, 7.53 (all m, 10H, 2 Ph). ^{13}C NMR (CDCl_3 , 125 MHz): δ 37.85-37.93 (m, Me); 76.62, 97.92 ($-\text{C}\equiv\text{C}-$); 102.72 (unsolv. t, C^4); 110.15 (tq, J 258.2, 41.2 Hz, CF_2); 118.16 (qt, J 287.5, 37.1 Hz, CF_3); 122.66, 125.65, 128.24, 128.67, 128.73, 129.64, 131.76, 132.77 (2 Ph); 141.45 (t, J 27.0 Hz, $\underline{\text{C}}-\text{CF}_2$); 161.75 ($\text{C}=\text{O}$). ^{19}F NMR (CDCl_3 , 470 MHz): δ 49.24 (br.s, 2F, CF_2); 100.83 (br.s, 3F, CF_3). IR: 1677 ($\text{C}=\text{O}$); 1574, 1589, 1488 ($\text{C}=\text{C}$); 1207-1157 (CF) cm^{-1} . Anal. calcd for $\text{C}_{20}\text{H}_{13}\text{F}_5\text{N}_2\text{O}$. C, 61.23; H, 3.34; N, 7.14. Найдено (%): C, 61.35; H, 3.23; N, 7.10.

Biological testing

Viruses and cells. We used the transplantable Vero cell cultures (green monkey kidney cells) obtained from the collection of cell cultures of the Vector Institute (Koltsovo, Novosibirsk region) and MDCK (ATCC CCL-34) from the collection of cell lines of the Saint Petersburg Pasteur Institute of Epidemiology and Microbiology. Vero cells were cultured in 96-well culture plates in DMEM medium with additive of 2% fetal bovine serum («HyClone», USA), 40 U/ml of gentamicin sulfate, and 2.5 U/ml of amphotericin B. MDCK cells were cultured in MEM medium with additive of 10% fetal bovine serum («HyClone», USA), 40 U/ml gentamicin sulfate and 2.5 U/ml amphotericin B. Cell suspension with a concentration of 105 cells/ml was placed in the wells of the plates in volume of 100 μl and cultured until a complete monolayer formation for 24 h at 37 °C in the presence of 5% CO_2 .

The same medium without serum was used as a support medium for culturing cells with viruses.

We used influenza virus A/Puerto Rico/8/34 (H1N1) from the collection of the Saint Petersburg Pasteur Institute of Epidemiology and Microbiology, and vaccine virus (VV, strain Copenhagen), herpes simplex virus type 1 (HSV-1, strain VR-3) and bovine diarrhea virus (BDV) (strain VC-1) obtained from the collection of the Vector Institute (Koltsovo, Novosibirsk region). The infectious titers of viruses were determined by titration in 96-well plates with monolayers of the corresponding line cells [4]. The results were evaluated visually according to the presence of the virus cytopathic action, the virus titer was calculated by the Spearman-Kerker method and represented in decimal logarithms of 50% tissue cytopathic doses in ml ($\lg \text{TCD}_{50}/\text{ml}$) [5].

Evaluation of cytotoxic properties of compounds

The investigation of toxicity of compounds was carried out based on evaluation of the cells viability using the reduction reaction of the tetrazolium dye MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2*H*-tetrazolium bromide) by cells in culture. Its intensity shows the degree of cell viability as a result of dye reduction by mitochondrial and partially cytoplasmic dehydrogenases.

The test compounds in the concentration range of 4-1000 µg/ml dissolved in the medium for cell cultivation were added to the plate wells in a volume of 200 µl and incubated for 72 h at 36 °C in an atmosphere of 5% CO₂. At the end of the incubation period, the cells were washed with MEM medium, and 100 µl of a solution (0.5 mg/ml) of MTT in the cell medium was added to the plate wells. The cells were incubated at 36 °C in an atmosphere of 5% CO₂ for 2 h and washed for 5 min with saline. The precipitate was dissolved in 100 µl of DMSO per well, and the optical density was measured using a Multiscan FC plate analyzer (Thermo Scientific) at a wavelength of 540 nm. Based on the obtained data, the 50% cytotoxic concentration (CC₅₀) was calculated, i.e. the concentration of the compound, which reduces the optical density in the wells by half compared to control cells without drugs.

Evaluation of antiviral activity of compounds

Determination of activity in relation to influenza virus A/Puerto Rico/8/34 (H1N1)

The compounds in appropriate concentrations were added to MDCK cells (0.1 ml per well). After 1 h of incubation, cells were infected with influenza virus A/Puerto Rico/8/34 (H1N1) (moi 0.01) and incubated for 72 h at 36 °C and 5% CO₂. After that, cell viability was assessed by MTT test as described in [6]. The cytoprotective activity of compounds was considered as their ability to increase the values of OD comparing to control wells (with virus only, no drugs). Based on the results obtained, the values of IC₅₀, i.e. concentration of compounds that result in 50% cells protection were calculated using GraphPad Prism 6.01 software. Values of IC₅₀ obtained in µg/ml were then calculated into micromoles (µM). For each compound the value of selectivity index (SI) was calculated as ratio of CC₅₀ to IC₅₀.

Determination of activity in relation to SVV, HSV-1, and VDC

The studied compounds were preliminarily dissolved in DMSO at a concentration of 20 mg/ml and stored in a freezer at -70 °C.

To test the antiviral activity of the compounds against VV, HSV-1, and BDV, a series of 5-fold dilutions of the samples were prepared (starting with a concentration of 400 µg/ml).

VV, HSV-1, and BDV were added to the plate wells at doses corresponding to a multiplicity of infection (moi) of 0.01. Viruses were cultured in cells in the presence of test compounds for 3 days. After this period, the cells viability in culture was assessed as described above. Based on the obtained data, the value of 50% inhibitory concentration (IC₅₀) was calculated,

i.e., the concentration of the compound leading to a 50% decrease in the cytodestructive effect of the virus.



Based on the CC_{50} and IC_{50} values, the selectivity index (SI) or the therapeutic index was calculated showing how many times the cytotoxic concentration is greater than the virus inhibiting concentration of the drug: $SI = CC_{50}/IC_{50}$.

References

- [1] O. V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, OLEX2 : a complete structure solution, refinement and analysis program, *J. Appl. Crystallogr.* 42 (2009) 339–341. doi:10.1107/S0021889808042726.
- [2] G.M. Sheldrick, Crystal structure refinement with SHELXL, *Acta Crystallogr. Sect. C Struct. Chem.* 71 (2015) 3–8. doi:10.1107/S2053229614024218.
- [3] N. Agafonova, E. Shchegolkov, Y. Burgart, V. Saloutin, A. Trefilova, G. Triandafilova, S. Solodnikov, V. Maslova, S. Borisevich, O. Krasnykh, S. Khursan, Synthesis and biological evaluation of polyfluoroalkylated antipyridines and their isomeric O-methylpyrazoles, *Med. Chem.* 14 (2018). doi:10.2174/1573406414666181106145435.
- [4] *Virology Methods Manual*, Elsevier, 1996. doi:10.1016/B978-0-12-465330-6.X5000-3.
- [5] L. Sachs, *Statistische Auswertungsmethoden*, Springer Berlin Heidelberg, Berlin, Heidelberg, 1972. doi:10.1007/978-3-662-10037-0.
- [6] N.A. Elkina, Y. V. Burgart, E. V. Shchegolkov, O.P. Krasnykh, V. V. Maslova, G.A. Triandafilova, S.S. Solodnikov, A.A. Muryleva, M.A. Misiurina, A. V. Slita, V. V. ZarubaeV, V.I. Saloutin, Competitive routes to cyclizations of polyfluoroalkyl-containing 2-tolylhydrazinylidene-1,3-diketones with 3-aminopyrazoles into bioactive pyrazoloazines, *J. Fluorine Chem.* 240 (2020) 109648. doi:10.1016/j.jfluchem.2020.109648.

Copies of ^1H , ^{13}C , and ^{19}F NMR spectra of compounds

^1H NMR spectrum of compound **4a** in $\text{DMSO-}d_6$



Current Data Parameters

NAME NNA304
 EXPNO 1
 PROCNO 1
 USER uralhmr


F2 - Acquisition Parameters

Date_ 20181212
 Time 13.12
 INSTRUM DRX400
 PROBHD 5 mm SEF 19F-1
 PULPROG zg30
 TD 32768
 SOLVENT DMSO
 NS 16
 DS 2
 SWH 6410.256 Hz
 FIDRES 0.195625 Hz
 AQ 2.5559540 sec
 RG 512
 DW 78.000 usec
 DE 20.00 usec
 TE 297.2 K
 D1 1.00000000 sec
 MCREST 0.00000000 sec
 MCWRK 0.01500000 sec
 ===== CHANNEL f1 =====
 NUC1 1H
 P1 20.00 usec
 PL1 0.00 dB
 SFO1 400.1328009 MHz

F2 - Processing parameters



SI 32768
 HZpPT 0.195625 Hz
 SF 400.1300024 MHz
 SR 2.39 Hz
 WDW EM
 LB 0.00 Hz
 GB 0
 -1SSB 0
 PC 4.00

¹³C NMR spectrum of compound **4a** in DMSO-*d*₆



NAME	NNA304
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20190123
Time	13.27
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	DMSO
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	1024
DS	8
AQ	0.6488564 sec
RG	203
TE	296.9 K
DE	6.50 usec
D1	0.80000001 sec
D11	0.03000000 sec
TD0	1
==== CHANNEL f1 =====	
NUC1	13C
P1	10.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
==== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	16.30 dB
PL13	19.30 dB
PL2W	0.00000000 W
PL12W	0.47519693 W
PL13W	0.23816262 W
SFO2	500.1320005 MHz
SI	32768
HZpPT	0.770646 Hz
SR	63.68 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0

¹⁹F NMR spectrum of compound **4a** in DMSO-*d*₆



Current Data Parameters

NAME NNA304
EXPNO 19
PROCNO 1
USER urahmr


F2 - Acquisition Parameters

Date_ 20181212
Time 13.15
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT DMSO
NS 8
DS 2
SWH 45351.473 Hz
FIDRES 0.346004 Hz
AQ 1.4451188 sec
RG 4597.6
DW 11.025 usec
DE 6.50 usec
TE 297.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec
==== CHANNEL f1 =====
NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4579891 MHz

F2 - Processing parameters



SI 131072
HZpPT 0.346004 Hz
SF 376.4371603 MHz
SR -124.73 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 4.00

¹H NMR spectrum of compound **4b** in CDCl₃





Current Data Parameters	
NAME	ESh705a
EXPNO	1
PROCNO	1
USER	uralnvr
F2 - Acquisition Parameters	
Date_	20191219
Time	13.31
INSTRUM	DRX400
PROBHD	5 mm SEF 19F-1
PULPROG	zg30
TD	32768
SOLVENT	CDCl3
NS	16
DS	2
SWH	6410.256 Hz
FIDRES	0.195625 Hz
AQ	2.5559540 sec
RG	512
DW	78.000 usec
DE	6.50 usec
TE	298.2 K
D1	1.0000000 sec
MCREST	0.0000000 sec
MCWRK	0.01500000 sec
===== CHANNEL f1 =====	
NUC1	1H
P1	20.00 usec
PL1	0.00 dB
SFO1	400.1328009 MHz
F2 - Processing parameters	
SI	32768
HZpPT	0.195625 Hz
SF	400.1300087 MHz
SR	8.72 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0
PC	4.00

¹³C NMR spectrum of compound **4b** in CDCl₃



NAME	ESh705a
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20191225
Time	19.36
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	65536
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.385323 Hz
NS	16384
DS	8
AQ	1.2976629 sec
RG	203
TE	295.8 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	16
==== CHANNEL f1 =====	
NUC1	13C
P1	10.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
==== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	16.30 dB
PL13	19.30 dB
PL2W	0.00000000 W
PL12W	0.47519693 W
PL13W	0.23816262 W
SFO2	500.1320005 MHz
SI	65536
HZpPT	0.385323 Hz
SR	2.23 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0

¹⁹F NMR spectrum of compound **4b** in CDCl₃



Current Data Parameters

NAME ESh705a
EXPNO 19
PROCNO 1
USER uralhmr

F2 - Acquisition Parameters

Date_ 20191219
Time 13.40
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 262144
SOLVENT CDCl₃
NS 16
DS 2
SWH 37664.785 Hz
FIDRES 0.143680 Hz
AQ 3.4800117 sec
RG 912.3
DW 13.275 usec
DE 6.50 usec
TE 298.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec
==== CHANNEL f1 =====
NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4523425 MHz

F2 - Processing parameters

SI 131072
HZpPT 0.287360 Hz
SF 376.4374801 MHz
SR 195.11 Hz
WDW EM
LB 0.20 Hz
GB 0
SSB 0
PC 3.00

¹H NMR spectrum of compound **4c** in CDCl₃



7.53
7.51
7.42
7.41
7.26

3.20

1.60

1.25

0.00



1.91
2.82

3.00


1.60

1.25

0.00


NAME	Esh706
EXPNO	1
PROCNO	1
USER	uralhmr
Date_	20200110
Time	14.21
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	CDCl ₃
TD	32768
SW	12.0160 ppm
O1P	5.000 ppm
FIDRES	0.183399 Hz
NS	16
DS	2
AQ	2.7263477 sec
RG	203
TE	295.6 K
DE	6.50 usec
D1	1.00000000 sec
TD0	1
==== CHANNEL f1 =====	
NUC1	1H
P1	12.00 usec
PL1	0.30 dB
PL1W	18.91792679 W
SFO1	500.1325007 MHz
SI	32768
HZpPT	0.183399 Hz
SR	11.57 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0

¹³C NMR spectrum of compound **4c** in CDCl₃




NAME	ESh706
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20200205
Time	18.28
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	28672
DS	8
AQ	0.6488564 sec
RG	203
TE	296.5 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	28
===== CHANNEL f1 =====	
NUC1	¹³ C
P1	9.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
===== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	¹ H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	17.00 dB
PL13	20.00 dB
PL2W	0.00000000 W
PL12W	0.40445811 W
PL13W	0.20270923 W
SFO2	500.1320005 MHz
SI	32768
HZpPT	0.770646 Hz
SR	1.55 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0



¹⁹F NMR spectrum of compound **4c** in CDCl₃



NAME	ESh706
EXPNO	19
PROCNO	1
USER	urahmr
Date_	20200110
Time	14.26
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	CDCl3
TD	131072
SW	99.6202 ppm
O1P	45.000 ppm
FIDRES	0.357628 Hz
NS	16
DS	2
AQ	1.3981513 sec
RG	203
TE	295.6 K
DE	6.50 usec
D1	1.00000000 sec
TD0	1
==== CHANNEL f1 ====	
NUC1	19F
P1	15.50 usec
PL1	-5.00 dB
PL1W	46.07103729 W
SFO1	470.5370532 MHz
SI	131072
HZpPT	0.357628 Hz
SR	400.40 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0





¹H NMR spectrum of compound **4d** in CDCl₃




Current Data Parameters	
NAME	ESh717
EXPNO	1
PROCNO	1
USER	uralnmr
F2 - Acquisition Parameters	
Date_	20200206
Time	12.38
INSTRUM	DRX400
PROBHD	5 mm SEF 19F-1
PULPROG	zg30
TD	32768
SOLVENT	CDCl3
NS	16
DS	2
SWH	5592.841 Hz
FIDRES	0.170680 Hz
AQ	2.9295092 sec
RG	1149.4
DW	89.400 usec
DE	6.00 usec
TE	297.2 K
D1	1.00000000 sec
MCREST	0.00000000 sec
MCWRK	0.01500000 sec
==== CHANNEL f1 =====	
NUC1	1H
P1	20.00 usec
PL1	0.00 dB
SFO1	400.1324008 MHz
F2 - Processing parameters	
SI	32768
HZpPT	0.170680 Hz
SF	400.1300091 MHz
SR	9.05 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0
PC	4.00

¹³C NMR spectrum of compound **4d** in CDCl₃



NAME	ESh717
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20200213
Time	17.13
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	34816
DS	8
AQ	0.6488564 sec
RG	203
TE	295.7 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	34
==== CHANNEL f1 =====	
NUC1	13C
P1	9.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
==== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	17.00 dB
PL13	20.00 dB
PL2W	0.00000000 W
PL12W	0.40445811 W
PL13W	0.20270923 W
SFO2	500.1320005 MHz
SI	32768
HZpPT	0.770646 Hz
SR	1.43 Hz
WDW	EM
LB	1.50 Hz
GB	0
SSB	0

¹⁹F NMR spectrum of compound **4d** in CDCl₃



Current Data Parameters

NAME ESh717
EXPNO 19
PROCNO 1
USER urahmr



F2 - Acquisition Parameters

Date_ 20200206
Time 12.48
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT CDCB
NS 16
DS 2
SWH 37664.785 Hz
FIDRES 0.287360 Hz
AQ 1.7400308 sec
RG 2298.8
DW 13.275 usec
DE 6.50 usec
TE 297.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec
==== CHANNEL f1 =====
NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4542247 MHz

F2 - Processing parameters

SI 131072
HZpPT 0.287360 Hz
SF 376.4374841 MHz
SR 199.13 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 3.00

¹H NMR spectrum of compound **5a** in CDCl₃



Current Data Parameters

NAME ESh811b
EXPNO 1
PROCNO 1
USER urahmr

F2 - Acquisition Parameters

Date_ 20210416
Time 13.41
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 32768
SOLVENT CDCl3
NS 16
DS 2
SWH 6410.256 Hz
FIDRES 0.195625 Hz
AQ 2.5559540 sec
RG 1625.5
DW 78.000 usec
DE 16.00 usec
TE 297.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec



==== CHANNEL f1 ====

NUC1 1H
P1 32.50 usec
PL1 -4.00 dB
SFO1 400.1328009 MHz

F2 - Processing parameters

SI 32768
HZpPT 0.195625 Hz
SF 400.1300092 MHz
SR 9.16 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 4.00

¹³C NMR spectrum of compound **5a** in CDCl₃





NAME ESh811b
 EXPNO 13
 PROCNO 1
 USER uralnmr
 Date_ 20210611
 Time 14.23
 INSTRUM AV500
 PROBHD 5 mm PABBO BB-
 PULPROG zgpg30
 SOLVENT CDCl3
 TD 32768
 SW 200.7838 ppm
 O1P 95.000 ppm
 FIDRES 0.770646 Hz
 NS 1024
 DS 8
 AQ 0.6488564 sec
 RG 203
 TE 296.1 K
 DE 6.50 usec
 D1 1.00000000 sec
 D11 0.03000000 sec
 TD0 1

==== CHANNEL f1 =====
 NUC1 13C
 P1 10.00 usec
 PL1 0.00 dB
 PL1W 115.29558563 W
 SFO1 125.7697360 MHz

==== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 75.00 usec
 PL2 120.00 dB
 PL12 16.30 dB
 PL13 19.30 dB
 PL2W 0.00000000 W
 PL12W 0.47519693 W
 PL13W 0.23816262 W
 SFO2 500.1320005 MHz
 SI 32768
 HZpPT 0.770646 Hz
 SR 5.28 Hz
 WDW EM
 LB 1.00 Hz
 GB 0
 SSB 0

¹⁹F NMR spectrum of compound **5a** in CDCl₃



Current Data Parameters

NAME ESh811b
EXPNO 19
PROCNO 1
USER uralhmr

F2 - Acquisition Parameters

Date_ 20210416
Time 13.47
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT CDCl3
NS 16
DS 2
SWH 45351.473 Hz
FIDRES 0.346004 Hz
AQ 1.4451188 sec
RG 2048
DW 11.025 usec
DE 6.50 usec
TE 297.2 K
D1 1.0000000 sec
MCREST 0.0000000 sec
MCWRK 0.01500000 sec


==== CHANNEL f1 =====

NUC1 19F
P1 20.25 usec
PL1 0.00 dB
SFO1 376.4561069 MHz

F2 - Processing parameters

SI 131072
HZpPT 0.346004 Hz
SF 376.4374880 MHz
SR 202.99 Hz
WDW EM
LB 0.01 Hz
GB 0
SSB 0
PC 4.00

¹H NMR spectrum of compound **5b** in CDCl₃



7.53
7.52
7.50
7.42
7.42
7.41
7.41
7.40
7.26


7.53
7.52
7.50

7.42
7.42
7.41
7.41
7.40

3.23

1.57

0.00



1.96
2.88

3.00



NAME ESh752
EXPNO 1
PROCNO 1
USER urahmr
Date_ 20210408
Time 15.42
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 32768
SW 14.0019 ppm
O1P 6.000 ppm
FIDRES 0.213709 Hz
NS 16
DS 2
AQ 2.3396852 sec
RG 203
TE 296.4 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1

==== CHANNEL f1 =====
NUC1 1H
P1 12.00 usec
PL1 0.30 dB
PL1W 18.91792679 W
SFO1 500.1330008 MHz
SI 32768
HZpPT 0.213709 Hz
SR 12.73 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0

12 11 10 9 8 7 6 5 4 3 2 1 0 -1

ppm 38

¹³C NMR spectrum of compound **5b** in CDCl₃



NAME	ESh752
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20201105
Time	18.12
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	32768
DS	8
AQ	0.6488564 sec
RG	203
TE	296.9 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	32



==== CHANNEL f1 =====

NUC1	13C
P1	9.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz

==== CHANNEL f2 =====

CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	17.00 dB
PL13	20.00 dB
PL2W	0.00000000 W
PL12W	0.40445811 W
PL13W	0.20270923 W
SFO2	500.1320005 MHz
SI	32768
HZpPT	0.770646 Hz
SR	1.28 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0


¹⁹F NMR spectrum of compound **5b** in CDCl₃



NAME ESh752
EXPNO 19
PROCNO 1
USER urahmr
Date_ 20210408
Time 15.46
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 131072
SW 99.6202 ppm
O1P 45.000 ppm
FIDRES 0.357628 Hz
NS 16
DS 2
AQ 1.3981513 sec
RG 203
TE 296.4 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1

==== CHANNEL f1 ====
NUC1 19F
P1 15.50 usec
PL1 -5.00 dB
PL1W 46.07103729 W
SFO1 470.5370532 MHz
SI 131072
HZpPT 0.357628 Hz
SR 403.23 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0


¹H NMR spectrum of compound **3a** in CDCl₃



NAME ESh695
EXPNO 1
PROCNO 1
USER uralnmr
Date_ 20190725
Time 13.25
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 32768
SW 14.0019 ppm
O1P 6.000 ppm
FIDRES 0.213709 Hz
NS 16
DS 2
AQ 2.3396852 sec
RG 181
TE 295.8 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1



==== CHANNEL f1 =====
NUC1 1H
P1 12.00 usec
PL1 0.30 dB
PL1W 18.91792679 W
SFO1 500.1330008 MHz
SI 32768
HZpPT 0.213709 Hz
SR 13.62 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0

¹³C NMR spectrum of compound **3a** in CDCl₃





NAME	ESh695
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20190731
Time	10.39
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	1024
DS	8
AQ	0.6488564 sec
RG	203
TE	297.3 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	1
===== CHANNEL f1 =====	
NUC1	13C
P1	10.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
===== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	0.30 dB
PL12	16.30 dB
PL13	19.30 dB
PL2W	18.91792679 W
PL12W	0.47519693 W
PL13W	0.23816262 W
SFO2	500.1320005 MHz
SI	65536
HZpPT	0.385323 Hz
SR	5.26 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0

¹⁹F NMR spectrum of compound **3a** in CDCl₃



```
NAME      ESh695
EXPNO     19
PROCNO    1
USER      urahmr
Date_     20190725
Time      13.32
INSTRUM   AV500
PROBHD    5 mm PABBO BB-
PULPROG   zg30
SOLVENT   CDCl3
TD         131072
SW         120.7506 ppm
O1P       55.000 ppm
FIDRES    0.433488 Hz
NS         16
DS         2
AQ         1.1534836 sec
RG         203
TE         295.8 K
DE         6.50 usec
D1         1.00000000 sec
TD0        1
===== CHANNEL f1 =====
NUC1      19F
P1         15.50 usec
PL1        -5.00 dB
PL1W       46.07103729 W
SFO1       470.5417584 MHz
SI         131072
HZpPT     0.433488 Hz
SR         405.65 Hz
WDW        EM
LB         0.00 Hz
GB         0
SSB        0
```

¹H NMR spectrum of compound **3c** in CDCl₃





Current Data Parameters
NAME ESh788c
EXPNO 1
PROCNO 1
USER uralnrmr

F2 - Acquisition Parameters
Date_ 20210421
Time 14.57
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 32768
SOLVENT CDCl₃
NS 16
DS 2
SWH 6410.256 Hz
FIDRES 0.195625 Hz
AQ 2.5559540 sec
RG 228.1
DW 78.000 usec
DE 16.00 usec
TE 297.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec

==== CHANNEL f1 ====
NUC1 1H
P1 32.50 usec
PL1 -4.00 dB
SFO1 400.1328009 MHz

F2 - Processing parameters
SI 32768
HZpPT 0.195625 Hz
SF 400.1300086 MHz
SR 8.58 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 3.00

¹⁹F NMR spectrum of compound **3c** in CDCl₃




Current Data Parameters
NAME ESh788c
EXPNO 19
PROCNO 1
USER urahmr

F2 - Acquisition Parameters
Date_ 20210421
Time 15.04
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 262144
SOLVENT CDCl3
NS 16
DS 2
SWH 49019.609 Hz
FIDRES 0.186995 Hz
AQ 2.6739187 sec
RG 724.1
DW 10.200 usec
DE 6.50 usec
TE 297.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec

==== CHANNEL f1 =====
NUC1 19F
P1 20.25 usec
PL1 0.00 dB
SFO1 376.4579891 MHz

F2 - Processing parameters
SI 262144
HZpPT 0.186995 Hz
SF 376.4374830 MHz
SR 198.00 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 4.00


¹H NMR spectrum of compound **3d** in CDCl₃



8.29
8.27
7.69
7.68
7.57
7.55
7.54
7.49
7.47
7.45
7.44
7.42
7.26

8.29
8.27
7.69
7.68
7.57
7.55
7.54
7.49
7.47
7.45
7.44
7.42

3.35
1.59
0.00




NAME	ESh828
EXPNO	1
PROCNO	1
USER	urahmr
Date_	20210903
Time	14.04
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	CDCl3
TD	32768
SW	16.0214 ppm
O1P	7.000 ppm
FIDRES	0.244532 Hz
NS	16
DS	2
AQ	2.0447731 sec
RG	181
TE	296.0 K
DE	6.50 usec
D1	1.00000000 sec
TD0	1

==== CHANNEL f1 =====

NUC1	1H
P1	12.00 usec
PL1	0.30 dB
PL1W	18.91792679 W
SFO1	500.1335009 MHz
SI	32768
HZpPT	0.244532 Hz
SR	11.22 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0

¹³C NMR spectrum of compound **3d** in CDCl₃





NAME ESh828
 EXPNO 13
 PROCNO 1
 USER uralnmr
 Date_ 20210903
 Time 14.12
 INSTRUM AV500
 PROBHD 5 mm PABBO BB-
 PULPROG zgpg30
 SOLVENT CDCl3
 TD 32768
 SW 200.7838 ppm
 O1P 95.000 ppm
 FIDRES 0.770646 Hz
 NS 3072
 DS 8
 AQ 0.6488564 sec
 RG 203
 TE 296.0 K
 DE 6.50 usec
 D1 0.85000002 sec
 D11 0.03000000 sec
 TD0 1

==== CHANNEL f1 ====
 NUC1 13C
 P1 10.00 usec
 PL1 0.00 dB
 PL1W 115.29558563 W
 SFO1 125.7697360 MHz

==== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 75.00 usec
 PL2 120.00 dB
 PL12 16.30 dB
 PL13 19.30 dB
 PL2W 0.00000000 W
 PL12W 0.47519693 W
 PL13W 0.23816262 W
 SFO2 500.1320005 MHz
 SI 65536
 HZpPT 0.385323 Hz
 SR 1.37 Hz
 WDW EM
 LB 1.00 Hz
 GB 0
 SSB 0

¹⁹F NMR spectrum of compound **3d** in CDCl₃




NAME	ESh828
EXPNO	19
PROCNO	1
USER	urahmr
Date_	20210903
Time	14.09
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	CDCl3
TD	131072
SW	120.7512 ppm
O1P	50.000 ppm
FIDRES	0.433488 Hz
NS	16
DS	2
AQ	1.1534836 sec
RG	203
TE	296.0 K
DE	6.50 usec
D1	1.00000000 sec
TD0	1

==== CHANNEL f1 ====


NUC1	19F
P1	15.50 usec
PL1	-5.00 dB
PL1W	46.07103729 W
SFO1	470.5394058 MHz
SI	131072
HZpPT	0.433488 Hz
SR	400.51 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0

¹H NMR spectrum of compound **3e** in CDCl₃



7.69
7.67
7.62
7.60
7.55
7.54
7.52
7.50
7.48
7.42
7.41
7.39
7.26

7.69
7.67
7.62
7.60
7.55
7.54
7.52
7.50
7.48
7.42
7.41
7.39
7.26



1.91
1.87
1.99
1.86
0.96
3.00
1.64



NAME ESh825
EXPNO 1
PROCNO 1
USER uralmr
Date_ 20210816
Time 13.39
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 32768
SW 16.0214 ppm
O1P 7.000 ppm
FIDRES 0.244532 Hz
NS 16
DS 2
AQ 2.0447731 sec
RG 101
TE 295.3 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1

==== CHANNEL f1 =====
NUC1 1H
P1 12.00 usec
PL1 0.30 dB
PL1W 18.91792679 W
SFO1 500.1335009 MHz
SI 32768
HZpPT 0.244532 Hz
SR 13.20 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0

14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1

ppm

¹³C NMR spectrum of compound **3e** in CDCl₃



NAME	ESh825
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20210816
Time	13.53
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	65536
SW	209.2368 ppm
O1P	100.000 ppm
FIDRES	0.401547 Hz
NS	2048
DS	8
AQ	1.2452340 sec
RG	203
TE	296.3 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TDO	1



==== CHANNEL f1 =====

NUC1	13C
P1	10.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7703648 MHz

===== CHANNEL f2 =====

CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	16.30 dB
PL13	19.30 dB
PL2W	0.00000000 W
PL12W	0.47519693 W
PL13W	0.23816262 W
SFO2	500.1320005 MHz
SI	65536
HZpPT	0.401547 Hz
SR	4.27 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0


¹⁹F NMR spectrum of compound **3e** in CDCl₃



NAME ESh825
EXPNO 19
PROCNO 1
USER uralhmr
Date_ 20210816
Time 13.43
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 131072
SW 120.7512 ppm
O1P 50.000 ppm
FIDRES 0.433488 Hz
NS 16
DS 2
AQ 1.1534836 sec
RG 203
TE 295.3 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1


==== CHANNEL f1 =====
NUC1 19F
P1 15.50 usec
PL1 -5.00 dB
PL1W 46.07103729 W
SFO1 470.5394058 MHz
SI 131072
HZpPT 0.433488 Hz
SR 390.01 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0

¹H NMR spectrum of compound **3f** in CDCl₃




7.77
7.68
7.66
7.65
7.63
7.54
7.52
7.50
7.49
7.42
7.41
7.39
7.26

7.77
7.68
7.66
7.65
7.63
7.54
7.52
7.50
7.49
7.42
7.41
7.26




NAME ESh826
EXPNO 1
PROCNO 1
USER uralnmr
Date_ 20210820
Time 16.45
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 32768
SW 16.0214 ppm
O1P 7.000 ppm
FIDRES 0.244532 Hz
NS 32
DS 2
AQ 2.0447731 sec
RG 203
TE 296.4 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1

==== CHANNEL f1 =====
NUC1 1H
P1 12.00 usec
PL1 0.30 dB
PL1W 18.91792679 W
SFO1 500.1335009 MHz
SI 32768
HZpPT 0.244532 Hz
SR 13.45 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0



¹³C NMR spectrum of compound **3f** in CDCl₃



NAME	ESH826
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20210820
Time	16.57
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	49152
DS	8
AQ	0.6488564 sec
RG	203
TE	297.1 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	48


==== CHANNEL f1 =====

NUC1	13C
P1	10.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz

==== CHANNEL f2 =====

CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	16.30 dB
PL13	19.30 dB
PL2W	0.00000000 W
PL12W	0.47519693 W
PL13W	0.23816262 W
SFO2	500.1320005 MHz
SI	65536
HZpPT	0.385323 Hz
SR	0.05 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0


¹⁹F NMR spectrum of compound **3f** in CDCl₃





— 0.00

NAME	ESh826
EXPNO	19
PROCNO	1
USER	uralnmr
Date_	20210820
Time	16.49
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	CDCl3
TD	131072
SW	120.7506 ppm
O1P	55.000 ppm
FIDRES	0.433488 Hz
NS	16
DS	2
AQ	1.1534836 sec
RG	203
TE	296.4 K
DE	6.50 usec
D1	1.00000000 sec
TD0	1

====CHANNEL f1====
NUC1 19F
P1 15.50 usec
PL1 -5.00 dB
PL1W 46.07103729 W
SFO1 470.5417584 MHz
SI 131072
HZpPT 0.433488 Hz
SR 398.60 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0




¹H NMR spectrum of compound **3g** in DMSO-*d*₆




NAME	ESH698
EXPNO	1
PROCNO	1
USER	uralnmr
Date_	20191001
Time	11.08
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	DMSO
TD	32768
SW	12.0160 ppm
O1P	5.000 ppm
FIDRES	0.183399 Hz
NS	16
DS	2
AQ	2.7263477 sec
RG	203
TE	296.6 K
DE	16.00 usec
D1	1.00000000 sec
TD0	1
==== CHANNEL f1 =====	
NUC1	1H
P1	12.00 usec
PL1	0.30 dB
PL1W	18.91792679 W
SFO1	500.1325007 MHz
SI	32768
HZpPT	0.183399 Hz
SR	5.33 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0

¹³C NMR spectrum of compound **3g** in DMSO-*d*₆



NAME	Esh698
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20191002
Time	10.57
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	DMSO
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	2048
DS	8
AQ	0.6488564 sec
RG	203
TE	297.1 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	2
===== CHANNEL f1 =====	
NUC1	13C
P1	10.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
===== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	16.30 dB
PL13	19.30 dB
PL2W	0.00000000 W
PL12W	0.47519693 W
PL13W	0.23816262 W
SFO2	500.1320005 MHz
SI	65536
HZpPT	0.385323 Hz
SR	62.03 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0


¹⁹F NMR spectrum of compound **3g** in DMSO-*d*₆




NAME	ESh698
EXPNO	19
PROCNO	1
USER	uralmr
Date_	20191001
Time	11.14
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	DMSO
TD	131072
SW	120.7506 ppm
O1P	55.000 ppm
FIDRES	0.433488 Hz
NS	16
DS	2
AQ	1.1534836 sec
RG	203
TE	296.6 K
DE	6.50 usec
D1	1.00000000 sec
TD0	1
=== CHANNEL f1 ===	
NUC1	19F
P1	15.50 usec
PL1	-5.00 dB
PL1W	46.07103729 W
SFO1	470.5417584 MHz
SI	131072
HZpPT	0.433488 Hz
SR	-3.69 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0

104.68

0.00



¹H NMR spectrum of compound **3h** in CDCl₃





Current Data Parameters	
NAME	ESh707
EXPNO	1
PROCNO	1
USER	uralnrmr

F2 - Acquisition Parameters	
Date_	20200131
Time	12.50
INSTRUM	DRX400
PROBHD	5 mm SEF 19F-1
PULPROG	zg30
TD	32768
SOLVENT	CDCl3
NS	16
DS	2
SWH	6410.256 Hz
FIDRES	0.195625 Hz
AQ	2.5559540 sec
RG	574.7
DW	78.000 usec
DE	6.00 usec
TE	297.2 K
D1	1.00000000 sec
MCREST	0.00000000 sec
MCWRK	0.01500000 sec
==== CHANNEL f1 =====	
NUC1	1H
P1	20.00 usec
PL1	0.00 dB
SFO1	400.1328009 MHz

F2 - Processing parameters	
SI	32768
HZpPT	0.195625 Hz
SF	400.1300099 MHz
SR	9.93 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0
PC	4.00

¹³C NMR spectrum of compound **3h** in CDCl₃



NAME	Esh707
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20200211
Time	19.46
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	65536
SW	209.2368 ppm
O1P	100.000 ppm
FIDRES	0.401547 Hz
NS	20480
DS	8
AQ	1.2452340 sec
RG	203
TE	296.6 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TDO	20
==== CHANNEL f1 ====	
NUC1	¹³ C
P1	9.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7703648 MHz
==== CHANNEL f2 ====	
CPDPRG2	waltz16
NUC2	¹ H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	17.00 dB
PL13	20.00 dB
PL2W	0.00000000 W
PL12W	0.40445811 W
PL13W	0.20270923 W
SFO2	500.1320005 MHz
SI	32768
HZpPT	0.803094 Hz
SR	3.36 Hz
WDW	EM
LB	1.50 Hz
GB	0
SSB	0

¹⁹C\F NMR spectrum of compound **3h** in CDCl₃

Current Data Parameters



NAME ESh707
EXPNO 19
PROCNO 1
USER uralhmr

F2 - Acquisition Parameters



Date_ 20200131
Time 12.54
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT CDCl₃
NS 16
DS 2
SWH 37664.785 Hz
FIDRES 0.287360 Hz
AQ 1.7400308 sec
RG 2298.8
DW 13.275 usec
DE 6.50 usec
TE 297.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec
==== CHANNEL f1 ====
NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4523425 MHz

F2 - Processing parameters

SI 131072
HZpPT 0.287360 Hz
SF 376.4374855 MHz
SR 200.54 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 3.00



¹H NMR spectrum of compound **3i** in CDCl₃



Current Data Parameters

NAME ESh714
 EXPNO 1
 PROCNO 1
 USER uralnmr

F2 - Acquisition Parameters

Date_ 20200312
 Time 14.27
 INSTRUM DRX400
 PROBHD 5 mm SEF 19F-1
 PULPROG zg30
 TD 32768
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 4789.272 Hz
 FIDRES 0.146157 Hz
 AQ 3.4210291 sec
 RG 812.7
 DW 104.400 usec
 DE 6.00 usec
 TE 298.2 K
 D1 1.00000000 sec
 MCREST 0.00000000 sec
 MCWRK 0.01500000 sec



==== CHANNEL f1 =====

NUC1 1H
 P1 20.00 usec
 PL1 0.00 dB
 SFO1 400.1320007 MHz

F2 - Processing parameters

SI 32768
 HZpPT 0.146157 Hz
 SF 400.1300090 MHz
 SR 8.97 Hz
 WDW EM
 LB 0.00 Hz
 GB 0
 SSB 0
 PC 4.00

¹³C NMR spectrum of compound **3i** in CDCl₃




NAME ESh714
 EXPNO 13
 PROCNO 1
 USER uralnmr
 Date_ 20200330
 Time 19.09
 INSTRUM AV500
 PROBHD 5 mm PABBO BB-
 PULPROG zgpg30
 SOLVENT CDCl3
 TD 65536
 SW 200.7838 ppm
 O1P 95.000 ppm
 FIDRES 0.385323 Hz
 NS 32768
 DS 8
 AQ 1.2976629 sec
 RG 203
 TE 297.2 K
 DE 6.50 usec
 D1 1.20000005 sec
 D11 0.03000000 sec
 TD0 32

==== CHANNEL f1 =====
 NUC1 13C
 P1 9.00 usec
 PL1 0.00 dB
 PL1W 115.29558563 W
 SFO1 125.7697360 MHz

==== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 75.00 usec
 PL2 120.00 dB
 PL12 17.00 dB
 PL13 20.00 dB
 PL2W 0.00000000 W
 PL12W 0.40445811 W
 PL13W 0.20270923 W
 SFO2 500.1320005 MHz
 SI 65536
 HZpPT 0.385323 Hz
 SR 3.54 Hz
 WDW EM
 LB 1.00 Hz
 GB 0
 SSB 0

¹⁹F NMR spectrum of compound **3i** in CDCl₃



Current Data Parameters

NAME ESh714
EXPNO 19
PROCNO 1
USER uralnmr

F2 - Acquisition Parameters

Date_ 20200312
Time 14.32
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT CDCB
NS 16
DS 2
SWH 37664.785 Hz
FIDRES 0.287360 Hz
AQ 1.7400308 sec
RG 2580.3
DW 13.275 usec
DE 6.50 usec
TE 298.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec



==== CHANNEL f1 ====

NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4542247 MHz

F2 - Processing parameters

SI 131072
HZpPT 0.287360 Hz
SF 376.4374841 MHz
SR 199.13 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 3.00

¹H NMR spectrum of compound **3j** in CDCl₃



Current Data Parameters


NAME ESh708
 EXPNO 1
 PROCNO 1
 USER uralnmr

F2 - Acquisition Parameters


Date_ 20200131
 Time 13.13
 INSTRUM DRX400
 PROBHD 5 mm SEF 19F-1
 PULPROG zg30
 TD 32768
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 6410.256 Hz
 FIDRES 0.195625 Hz
 AQ 2.5559540 sec
 RG 574.7
 DW 78.000 usec
 DE 6.00 usec
 TE 297.2 K
 D1 1.00000000 sec
 MCREST 0.00000000 sec
 MCWRK 0.01500000 sec
 ===CHANNEL f1 ===
 NUC1 1H
 P1 20.00 usec
 PL1 0.00 dB
 SFO1 400.1328009 MHz

F2 - Processing parameters

SI 32768
 HZpPT 0.195625 Hz
 SF 400.1300102 MHz
 SR 10.25 Hz
 WDW EM
 LB 0.00 Hz
 GB 0
 SSB 0
 PC 4.00





¹³C NMR spectrum of compound **3j** in CDCl₃



NAME	ESh708
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20200210
Time	17.43
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	32768
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.770646 Hz
NS	32768
DS	8
AQ	0.6488564 sec
RG	203
TE	295.9 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	32
==== CHANNEL f1 =====	
NUC1	13C
P1	9.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
==== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	17.00 dB
PL13	20.00 dB
PL2W	0.00000000 W
PL12W	0.40445811 W
PL13W	0.20270923 W
SFO2	500.1320005 MHz
SI	32768
HZpPT	0.770646 Hz
SR	2.16 Hz
WDW	EM
LB	1.50 Hz
GB	0
SSB	0

¹⁹F NMR spectrum of compound **3j** in CDCl₃



Current Data Parameters

NAME ESh708
EXPNO 19
PROCNO 1
USER urahmr


F2 - Acquisition Parameters

Date_ 20200131
Time 13.17
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT CDCl3
NS 16
DS 2
SWH 37664.785 Hz
FIDRES 0.287360 Hz
AQ 1.7400308 sec
RG 2298.8
DW 13.275 usec
DE 6.50 usec
TE 297.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec
==== CHANNEL f1 =====
NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4523425 MHz

F2 - Processing parameters

SI 131072
HZpPT 0.287360 Hz
SF 376.4374848 MHz
SR 199.78 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 3.00

¹H NMR spectrum of compound **3k** in CDCl₃



Current Data Parameters

NAME ESh715
EXPNO 1
PROCNO 1
USER uralnmr

F2 - Acquisition Parameters

Date_ 20200312
Time 14.39
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 32768
SOLVENT CDCl3
NS 16
DS 2
SWH 4789.272 Hz
FIDRES 0.146157 Hz
AQ 3.4210291 sec
RG 812.7
DW 104.400 usec
DE 6.00 usec
TE 298.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec



==== CHANNEL f1 ====

NUC1 1H
P1 20.00 usec
PL1 0.00 dB
SFO1 400.1320007 MHz

F2 - Processing parameters

SI 32768
HZpPT 0.146157 Hz
SF 400.1300092 MHz
SR 9.23 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 4.00

¹³C NMR spectrum of compound **3k** in CDCl₃




NAME ESh715
 EXPNO 13
 PROCNO 1
 USER uralnmr
 Date_ 20200325
 Time 19.03
 INSTRUM AV500
 PROBHD 5 mm PABBO BB-
 PULPROG zgpg30
 SOLVENT CDCl3
 TD 32768
 SW 200.7838 ppm
 O1P 95.000 ppm
 FIDRES 0.770646 Hz
 NS 30720
 DS 8
 AQ 0.6488564 sec
 RG 203
 TE 296.6 K
 DE 6.50 usec
 D1 1.00000000 sec
 D11 0.03000000 sec
 TD0 30

==== CHANNEL f1 =====
 NUC1 13C
 P1 9.00 usec
 PL1 0.00 dB
 PL1W 115.29558563 W
 SFO1 125.7697360 MHz

==== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 75.00 usec
 PL2 120.00 dB
 PL12 17.00 dB
 PL13 20.00 dB
 PL2W 0.00000000 W
 PL12W 0.40445811 W
 PL13W 0.20270923 W
 SFO2 500.1320005 MHz
 SI 65536
 HZpPT 0.385323 Hz
 SR -2.56 Hz
 WDW EM
 LB 1.00 Hz
 GB 0
 SSB 0

¹³C NMR spectrum of compound **3k** in CDCl₃



Current Data Parameters

NAME ESh715
EXPNO 19
PROCNO 1
USER uralnmr

F2 - Acquisition Parameters

Date_ 20200312
Time 14.42
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT CDCl3
NS 16
DS 2
SWH 37664.785 Hz
FIDRES 0.287360 Hz
AQ 1.7400308 sec
RG 2580.3
DW 13.275 usec
DE 6.50 usec
TE 298.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec



==== CHANNEL f1 =====

NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4542247 MHz

F2 - Processing parameters

SI 131072
HZpPT 0.287360 Hz
SF 376.4374837 MHz
SR 198.74 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 3.00

¹H NMR spectrum of compound **3i** in CDCl₃



Current Data Parameters

NAME ESh722
EXPNO 1
PROCNO 1
USER uralhmr

F2 - Acquisition Parameters

Date_ 20200312
Time 14.49
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 32768
SOLVENT CDCl3
NS 16
DS 2
SWH 4789.272 Hz
FIDRES 0.146157 Hz
AQ 3.4210291 sec
RG 812.7
DW 104.400 usec
DE 6.00 usec
TE 298.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec



==== CHANNEL f1 =====

NUC1 1H
P1 20.00 usec
PL1 0.00 dB
SFO1 400.1320007 MHz

F2 - Processing parameters


SI 32768
HZpPT 0.146157 Hz
SF 400.1300093 MHz
SR 9.28 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 4.00

¹³C NMR spectrum of compound **3i** in CDCl₃



NAME	ESh722
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20200320
Time	18.26
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	65536
SW	200.7838 ppm
O1P	95.000 ppm
FIDRES	0.385323 Hz
NS	32768
DS	8
AQ	1.2976629 sec
RG	203
TE	296.6 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	32
===== CHANNEL f1 =====	
NUC1	13C
P1	9.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7697360 MHz
===== CHANNEL f2 =====	
CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	17.00 dB
PL13	20.00 dB
PL2W	0.00000000 W
PL12W	0.40445811 W
PL13W	0.20270923 W
SFO2	500.1320005 MHz
SI	131072
HZpPT	0.192661 Hz
SR	1.58 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0

¹⁹F NMR spectrum of compound **3I** in CDCl₃




Current Data Parameters
NAME ESh722
EXPNO 19
PROCNO 1
USER urahmr

F2 - Acquisition Parameters
Date_ 20200312
Time 14.52
INSTRUM DRX400
PROBHD 5 mm SEF 19F-1
PULPROG zg30
TD 131072
SOLVENT CDCl₃
NS 16
DS 2
SWH 37664.785 Hz
FIDRES 0.287360 Hz
AQ 1.7400308 sec
RG 2580.3
DW 13.275 usec
DE 6.50 usec
TE 298.2 K
D1 1.00000000 sec
MCREST 0.00000000 sec
MCWRK 0.01500000 sec

==== CHANNEL f1 =====
NUC1 19F
P1 10.10 usec
PL1 0.00 dB
SFO1 376.4542247 MHz

F2 - Processing parameters
SI 131072
HZpPT 0.287360 Hz
SF 376.4374823 MHz
SR 197.29 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0
PC 3.00

¹H NMR spectrum of compound **6a** in CDCl₃




7.55
7.55
7.54
7.54
7.53
7.53
7.51
7.43
7.42
7.41
7.34
7.34
7.33
7.26

3.27

1.58

-0.00

7.55
7.55
7.54
7.54
7.53
7.53
7.51
7.43
7.42
7.41
7.34
7.34
7.33
7.26




3.86
2.90
2.84

3.00

NAME ESh782
EXPNO 1
PROCNO 1
USER uralnmr
Date_ 20210322
Time 14.35
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 32768
SW 14.0019 ppm
O1P 6.000 ppm
FIDRES 0.213709 Hz
NS 16
DS 0
AQ 2.3396852 sec
RG 203
TE 296.3 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1

==== CHANNEL f1 ====
NUC1 1H
P1 12.00 usec
PL1 0.30 dB
PL1W 18.91792679 W
SFO1 500.1330008 MHz
SI 32768
HZpPT 0.213709 Hz
SR 12.68 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0

¹³C NMR spectrum of compound **6a** in CDCl₃




NAME ESI1702
EXPNO 13
PROCNO 1
USER uralnmr
Date_ 20210405
Time 10.56
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zgpg30
SOLVENT CDCl3
TD 32768
SW 200.7838 ppm
O1P 95.000 ppm
FIDRES 0.770646 Hz
NS 1024
DS 8
AQ 0.6488564 sec
RG 203
TE 297.0 K
DE 6.50 usec
D1 0.85000002 sec
D11 0.03000000 sec
TD0 1

==== CHANNEL f1 =====
NUC1 13C
P1 10.00 usec
PL1 0.00 dB
PL1W 115.29558563 W
SFO1 125.7697360 MHz

==== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
PCPD2 75.00 usec
PL2 120.00 dB
PL12 16.30 dB
PL13 19.30 dB
PL2W 0.00000000 W
PL12W 0.47519693 W
PL13W 0.23816262 W
SFO2 500.1320005 MHz
SI 65536
HZpPT 0.385323 Hz
SR 5.13 Hz
WDW EM
LB 1.00 Hz
GB 0
SSB 0


¹⁹H NMR spectrum of compound **6a** in CDCl₃





100.83

NAME ESh782
EXPNO 19
PROCNO 1
USER uralnmr
Date_ 20210322
Time 14.37
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 131072
SW 120.7506 ppm
O1P 55.000 ppm
FIDRES 0.433488 Hz
NS 8
DS 2
AQ 1.1534836 sec
RG 203
TE 296.3 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1


==== CHANNEL f1 =====
NUC1 19F
P1 15.50 usec
PL1 -5.00 dB
PL1W 46.07103729 W
SFO1 470.5417584 MHz
SI 131072
HZpPT 0.433488 Hz
SR 402.41 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0




¹H NMR spectrum of compound **6b** in CDCl₃



NAME	ESh824
EXPNO	1
PROCNO	1
USER	uralhmr
Date_	20210809
Time	17.38
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zg30
SOLVENT	CDCl3
TD	32768
SW	14.0019 ppm
O1P	6.000 ppm
FIDRES	0.213709 Hz
NS	16
DS	2
AQ	2.3396852 sec
RG	101
TE	295.1 K
DE	6.50 usec
D1	1.50000000 sec
TD0	1
==== CHANNEL f1 =====	
NUC1	1H
P1	12.00 usec
PL1	0.30 dB
PL1W	18.91792679 W
SFO1	500.1330008 MHz
SI	32768
HZpPT	0.213709 Hz
SR	12.89 Hz
WDW	EM
LB	0.00 Hz
GB	0
SSB	0



¹³C NMR spectrum of compound **6b** in CDCl₃



NAME	ESh824
EXPNO	13
PROCNO	1
USER	uralnmr
Date_	20210809
Time	18.01
INSTRUM	AV500
PROBHD	5 mm PABBO BB-
PULPROG	zgpg30
SOLVENT	CDCl3
TD	65536
SW	209.2368 ppm
O1P	100.000 ppm
FIDRES	0.401547 Hz
NS	24576
DS	8
AQ	1.2452340 sec
RG	203
TE	296.3 K
DE	6.50 usec
D1	1.00000000 sec
D11	0.03000000 sec
TD0	24


==== CHANNEL f1 =====

NUC1	13C
P1	10.00 usec
PL1	0.00 dB
PL1W	115.29558563 W
SFO1	125.7703648 MHz

==== CHANNEL f2 =====

CPDPRG2	waltz16
NUC2	1H
PCPD2	75.00 usec
PL2	120.00 dB
PL12	16.30 dB
PL13	19.30 dB
PL2W	0.00000000 W
PL12W	0.47519693 W
PL13W	0.23816262 W
SFO2	500.1320005 MHz
SI	32768
HZpPT	0.803094 Hz
SR	3.29 Hz
WDW	EM
LB	1.00 Hz
GB	0
SSB	0

¹⁹F NMR spectrum of compound **6b** in CDCl₃



NAME ESh824
EXPNO 19
PROCNO 1
USER uralnmr
Date_ 20210809
Time 17.44
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
SOLVENT CDCl3
TD 131072
SW 99.6202 ppm
O1P 45.000 ppm
FIDRES 0.357628 Hz
NS 16
DS 2
AQ 1.3981513 sec
RG 203
TE 295.1 K
DE 6.50 usec
D1 1.00000000 sec
TD0 1

==== CHANNEL f1 =====
NUC1 19F
P1 15.50 usec
PL1 -5.00 dB
PL1W 46.07103729 W
SFO1 470.5370532 MHz
SI 131072
HZpPT 0.357628 Hz
SR 395.82 Hz
WDW EM
LB 0.00 Hz
GB 0
SSB 0

